Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIB, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Next Previous
X
Search
Trial Profile

A Phase IIB, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Revefenacin (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Mylan Pharmaceuticals Inc.

    • Most Recent Events

    • 29 Oct 2020 Results of pooled analysis of data pooled from three phase II and two phase III studies (NCT03064113, NCT01704404, NCT02040792, NCT02459080, and NCT02512510) assessing the pharmacokinetics of Revefenacin and its major metabolite, published in the Clinical Pharmacokinetics
    • 20 May 2015 According to Theravance Biopharma media release, results presented at the American Thoracic Society (ATS) 2015 International Conference.
    • 20 May 2015 Results published in the Theravance Biopharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top